摘要
目的探讨新疆维吾尔自治区无EGFR突变的Ⅳ期维吾尔族NSCLC患者中kinesin family member 5B(KIF5B)-rearranged during transfection(RET)融合基因和棘皮动物微管相关类蛋白4(echinoderm microtubule-associated protein-like 4,EML4)-间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因的阳性率及其临床病理特征,并进行生存分析。方法分别采用RT-PCR/Sanger DNA测序法和FISH法/Ventana全自动免疫组织化学法检测90例非EGFR基因突变的Ⅳ期NSCLC维吾尔族患者中KIF5B-RET融合基因和EML4-ALK融合基因的表达情况,并进行随访。结果 90例无EGFR突变的Ⅳ期NSCLC患者中,检测到KIF5B-RET融合基因6例(6.7%),EML4-ALK融合基因12例(13.3%),病理类型均为腺癌。KIF5B-RET和EML4-ALK融合基因阳性率在病理类型方面比较,差异均具有统计学意义(均P<0.05),而在性别、年龄、吸烟史、有无淋巴结转移及分化程度方面比较,差异均无统计学意义(均P>0.05)。生存分析显示,KIF5B-RET融合基因阳性的患者与阴性患者中位总生存期比较,差异无统计学意义(17.5个月vs 15.8个月,P>0.05);EML4-ALK融合基因阳性的患者与阴性患者中位总生存期比较,差异无统计学意义(17.3个月vs 16.2个月,P>0.05)。结论对无EGFR突变的患者,KIF5B-RET与EML4-ALK基因融合突变状态尚不能作为评估Ⅳ期维吾尔族NSCLC患者预后的独立因素。
Objective To investigate the positive rates of kinesin family member 5 B（ KIF5 B） and rearranged during transfection（ RET） fusion gene and echinoderm microtubule-associated protein-like 4（ EML4） and anaplastic lymphoma kinase（ ALK） fusion gene,as well as the clinical pathological characteristics in EGFR negative,stage Ⅳ Uygur NSCLC patients of Xinjiang Uygur Autonomous Region. The survival analysis of the patients was also conducted. Methods The expression of KIF5 B-RET and EML4-ALK fusion genes was examined by RT-PCR,Sanger DNA sequencing,FISH and Ventana IHC methods in 90 cases of EGFR negative,stage Ⅳ Uygur NSCLC patients. These patients were followed-up to record the clinical outcome. Results Among the 90 patients of EGFR negative stage Ⅳ NSCLC,6 cases（ 6. 7%） had positive expression of KIF5 B-RET fusion gene,and 12 cases（ 13. 3%） had positive EML4-ALK. All positive cases were adenocarcinoma. The expressions of KIF5 B-RET and EML4-ALK were both significantly related with the pathological type（ both P〈0. 05）,but were not related with gender,age,smoking history,lymph node metastasis or differentiation degree（ all P〉0. 05）. Besides,survival analysis showed that there was no significant difference in the median overall survival rates between the KIF5 B-RET positive and the KIF5 B-RET negative patients（ 17. 5 months vs 15. 8 months,P〉0. 05）.Similarly,the median overall survival rates were similar between the EML4-ALK positive and the EML4-ALK negative patients（ 17. 3 months vs 16. 2 months,P〉0. 05）. Conclusion For EGFR negative stage Ⅳ NSCLC Uygur patients,the expression status of KIF5 B-RET or EML4-ALK fusion gene cannot be used as an independent factor in assessing the prognosis.
出处
《实用肿瘤杂志》
CAS
2018年第1期47-53,共7页
Journal of Practical Oncology
基金
乌鲁木齐市科学技术计划项目(Y161310008)
